default author photo

Laina D. Mercer

PATH

2201 Westlake Avenue, Suite 200

Seattle, WA 98121

United States

SCHOLARLY PAPERS

4

DOWNLOADS

386

TOTAL CITATIONS

1

Scholarly Papers (4)

1.

Safety and Immunogenicity of a Nipah Virus Vaccine (Hev-Sg-V) in Adults: A Single-Centre, Randomised, Observer-Blind, Placebo-Controlled, Phase 1 Study

Number of pages: 31 Posted: 30 May 2024
Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, PATH, PATH, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Auro Vaccines LLC, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, PATH, PATH, PATH, PATH, PATH, PATH, PATH and PATH
Downloads 162 (464,454)
Citation 1

Abstract:

Loading...

Nipah virus, vaccine, randomised clinical trial, infectious diseases

2.

Immunogenicity and Safety of Escherichia Coli-Produced Bivalent Human Papillomavirus Vaccine in Girls 9–14 Years of Age in Low- and Middle-Income Countries: Final Data of Randomized Controlled Trial

Number of pages: 34 Posted: 08 Nov 2024
Agogo Malaria Research Centre, PATH, Kwame Nkrumah University of Science and Technology, Ghana, PATH, PATH, Kwame Nkrumah University of Science and Technology, Ghana, International Vaccine Institute, International Centre for Diarrheal Disease Research (icddr,b), Government of the United States of America - HPV Serology Laboratory, PATH, Government of the United States of America - HPV Serology Laboratory, - Infectious Disease Division, PATH, PATH and - Infectious Diseases Division
Downloads 118 (608,822)

Abstract:

Loading...

Human papillomavirus (HPV), HPV vaccine, immunization, immunobridging, one-dose immunogenicity

3.

Safety and Immunogenicity of an Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam

Number of pages: 28 Posted: 10 Feb 2022
National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, affiliation not provided to SSRN, Hanoi Medical University, Hanoi Medical University, Hanoi Medical University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Mahidol University, Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), University of Texas at Austin - Department of Molecular Biosciences, affiliation not provided to SSRN, QBI Coronavirus Research Group (QCRG), Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, Mount Sinai School of Medicine - Department of Microbiology, affiliation not provided to SSRN, affiliation not provided to SSRN, Icahn School of Medicine at Mount Sinai - Department of Microbiology, affiliation not provided to SSRN, affiliation not provided to SSRN, PATH, PATH, PATH, PATH, PATH, PATH, PATH, PATH and PATH
Downloads 64 (933,592)

Abstract:

Loading...

SARS-CoV-2, COVID-19, Newcastle disease virus, Egg-based vaccine

4.

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing Sars-Cov-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial

Number of pages: 26 Posted: 30 May 2024
National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, National Institute of Hygiene and Epidemiology, affiliation not provided to SSRN, PATH, La Jolla Institute for Allergy and Immunology (LIAI), affiliation not provided to SSRN, PATH, PATH, PATH, PATH, La Jolla Institute for Allergy and Immunology (LIAI), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, La Jolla Institute for Allergy and Immunology (LIAI) - Division of Vaccine Discovery, PATH, Icahn School of Medicine at Mount Sinai - Department of Microbiology and La Jolla Institute for Allergy and Immunology (LIAI)
Downloads 42 (1,170,409)

Abstract:

Loading...

SARS-CoV-2, COVID-19, Newcastle disease virus, Egg-based vaccine, Phase II clinical trial